NC
RVLP

Nexthera Capital’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Nexthera Capital’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-120,620
Closed -$935K – 32
2018
Q4 		$935K Buy
+120,620
New +$965K 0.39% 21

Other funds holding RVLP

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Nexthera Capital's RVLP Position: Q1 2019 in Review

Nexthera Capital sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q1 2019, closing a stake of 120,620 shares — an estimated $935K sold.

Nexthera Capital first reported a position in RVLP in Q4 2018 and held it in 1 quarter. The position peaked at $935K in Q4 2018. 36 funds tracked by Wall St. Rank hold RVLP as of Q1 2019.

  • Nexthera Capital reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • Nexthera Capital sold 120,620 RVL Pharmaceuticals plc Ordinary Shares shares in Q1 2019, an estimated $935K.
  • Nexthera Capital first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 1 quarter.
  • Nexthera Capital's RVL Pharmaceuticals plc Ordinary Shares position peaked at $935K in Q4 2018.
  • 36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q1 2019.

Based on Nexthera Capital's 13F filing for Q1 2019, filed 15 May 2019.